Background: N-2-methoxybenzyl-phenethylamines (NBOMe drugs) are newly used
Introduction
New psychoactive substances are constantly emerging on the illicit drug market and typically sold via the Internet. Of particular interest are N-2-methoxybenzyl-phenethylamines (NBOMe drugs), which are novel and reportedly very potent hallucinogens that have been increasingly used recreationally (Forrester, 2014; Hill et al., 2013; Ninnemann and Stuart, 2013; Rose et al., 2013; Walterscheid et al., 2014; Wood et al., 2015; Zuba, 2012) , with additional potential use as radiotracers (Ettrup et al., 2011; Ettrup et al., 2010) . Recreationally used NBOMe drugs include 25I-NBOMe, 25C-NBOMe, 25B-NBOMe, and 25D-MBOMe (Armenian and Gerona, 2014; Poklis et al., 2014; Rose et al., 2013) , which are derivatives of 2,5-dimethoxy-4-substituted phenethylamines (2C drugs; Dean et al., 2013; Hill and Thomas, 2011; Shulgin and Shulgin, 1991) . N-2-methoxybenzyl substitution enhances the potency of 2C drugs at serotonergic 5-hydroxytryptamine-2A (5-HT 2A ) receptors, resulting in exceptionally potent 5-HT 2A receptor agonists (Braden et al., 2006; Heim, 2004; Nichols et al., 2015) with strong hallucinogenic properties in animals and humans (Halberstadt and Geyer, 2014; Srisuma et al., 2015) .
Pharmacological interactions between NBOMe drugs and 5-HT 2 receptors have been well characterized for some compounds of this novel drug family (Blaazer et al., 2008; Braden et al., 2006; Ettrup et al., 2011; Ettrup et al., 2010; Hansen et al., 2014; Nichols et al., 2008) . However, systematic characterizations of the effects of a larger series of NBOMe drugs at a wider range of relevant human receptors and comparisons with their 2C parent drugs are lacking. Importantly, NBOMe drugs have been reported to produce psycho-and cardiovascular stimulant effects, in addition to hallucinations. Specifically, sympathomimetic toxicity, including tachycardia, hypertension, mydriasis, agitation, and hyperthermia, is commonly reported in cases of acute NBOMe drug intoxication (Hill et al., 2013; Rose et al., 2013; Srisuma et al., 2015; Stellpflug et al., 2014; Wood et al., 2015) . Pharmacologically, compounds of the 2C series, including 2C-C, 2C-E, and 2C-I, inhibit the norepinephrine (NE) and serotonin transporters (NET and SERT, respectively), similar to amphetamines, although with only very low potency (Eshleman et al., 2014; Nagai et al., 2007) .
These findings raise the question of whether NBOMe drugs may have similar but more potent stimulant-type pharmacological properties, including inhibition of the NET, dopamine (DA) transporter (DAT), and SERT, or interactions with adrenergic α 1 receptors that lead to vasoconstriction.
We assessed the in vitro pharmacology of a series of NBOMe drugs compared with their 2C parent drugs. We characterized the binding affinity profiles at monoamine receptors and DAT, NET, and SERT inhibition potencies. We also determined the functional 5-HT 2A receptor activation potencies because 5-HT 2A receptors mediate hallucinogenic effects (Nichols, 2004) . The prototypical serotonergic hallucinogen lysergic acid diethylamide (LSD) was included as a comparator drug (Nichols, 2004; Passie et al., 2008) . B, 2C-C, 2C-D, 2C-E, 2C-H, 2C-I, 2C-N, 2C-P, 2C-T-2, 2C-T-4, 2C-T-7, mescaline, 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25E-NBOMe, 25H-NBOMe, 25I-NBOMe, 25N-NBOMe, 25P-NBOMe, 25T2-NBOMe, 25T4-NBOMe, 25T7-NBOMe, and mescaline-NBOMe were synthesized by Lipomed (Arlesheim, Switzerland) for this study at no cost. All of the compounds were used as hydrochloride salts. Purity was > 98% for all of the substances. 
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Radioligand receptor and transporter binding assays
The radioligand binding assays were performed as described previously (Hysek et al., 2012; Simmler et al., 2013 washed with HBSS (Gibco) and 20 mM HEPES (assay buffer; Gibco) using an EMBLA cell washer, and 100 µl assay buffer was added. The plate was placed in a fluorescence imaging plate reader (FLIPR), and 25 µl of the test substances diluted in assay buffer was added online. The increase in fluorescence was then measured.
EC 50 values were derived from the concentration-response curves using nonlinear regression. Efficacy (maximal activity) is expressed relative to the activity of 5-HT, which was used as a control set to 100%.
Inhibition of the human NET, DAT, and SERT was assessed in HEK 293 cells that were stably transfected with transporters as specified previously (Hysek et al., 2012) . Briefly, the cells were suspended in uptake buffer and incubated for 10 min with different concentrations of the test substances. The corresponding radiolabeled After 10 min, uptake was stopped by separating the cells from the buffer using centrifugation through silicone oil (Hysek et al., 2012) . The centrifugation tubes were frozen in liquid nitrogen and cut to separate the cell pellet from the silicone oil and assay buffer layers. The cell pellet was then lysed. Scintillation fluid was added, and radioactivity was counted on a β-counter. Nonspecific uptake was determined for each experiment in the presence of 10 µM fluoxetine for SERT cells, 10 µM nisoxetine for NET cells, and 10 µM mazindol for DAT cells and subtracted from the total counts to yield specific uptake (100%). The data were fitted by non-linear regression to variable slope sigmoidal dose-response curves (bottom = 0%), and IC 50 values were calculated using Prism software (GraphPad, San Diego, CA, USA).
Cytotoxicity
To confirm cell integrity during the pharmacological assays, cytotoxicity was assessed using the ToxiLight bioassay (Lonza, Basel, Switzerland) according to the manufacturer's instructions. The assay quantitatively measures the release of adenylate kinase from damaged cells, providing a highly sensitive method of measuring cytolysis (Crouch et al., 1993) . Cells that were grown in 96-well plates were exposed to the compounds at a high concentration of 100 µM. All of the test conditions contained 0.1% (v:v) dimethylsulfoxide, which is non-toxic at this concentration and was also used as a negative control. Triton X-100 (0.1%, SigmaAldrich, Buchs, Switzerland) lyses cells and was used as a positive control. After 4 h incubation at 37C, 10 µl of the supernatant per well was removed and combined with 50 µl of ToxiLight reagent, and luminescence was recorded using a Tecan
Infinite 200 Pro plate reader (Tecan, Männedorf, Switzerland). Table 1 Specifically, all of the NBOMe drugs and LSD showed high-affinity binding to IC 50 values for monoamine uptake inhibition are listed in Table 3 . The 2C drugs did not inhibit or only very weakly inhibited (IC 50 > 10 µM) monoamine uptake.
Results
Interactions with serotonin receptors
Binding to monoamine receptors and transporters
N-2-methoxybenzyl substitution consistently enhanced monoamine uptake inhibition potency approximately two-to 15-fold for the NET, two-to five-fold for the DAT, and two-to 26-fold for the SERT. As a result, 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25E-NBOMe, 25H-NBOMe, and 25I-NBOMe blocked the NET and/or SERT at 5-10 µM concentrations. LSD did not inhibit any of the monoamine transporters.
Cytotoxicity
None of the compounds produced cytotoxicity after 4 h incubation at 37C, with the exception of 25T7-NBOMe. 25T7-NBOMe became toxic after 4 h incubation at 100 µM (but not 10 µM). Because the assays lasted less than 4 h, this toxicity did not affect the data.
Discussion
We The 5-HT 2A receptor mediates hallucinogenic drug properties (Halberstadt and Geyer, 2011; Nelson et al., 1999; Nichols, 2004; Vollenweider et al., 1998) and is therefore considered the key target of hallucinogenic phenethylamines, including 2C
and NBOMe drugs (Braden et al., 2006; Halberstadt, 2015; Halberstadt and Geyer, 2014) . receptor affinity correlates with hallucinogenic drug potency in humans (Halberstadt, 2015; Titeler et al., 1988) , and NBOMe drugs can be expected to be extremely potent hallucinogens in vivo. Indeed, higher incidences of hallucinations and delusions have been reported in patients with NBOMe compared with 2C drug intoxication (Forrester, 2013 (Forrester, , 2014 Srisuma et al., 2015) . suggesting that additional ligand-receptor interactions contribute to receptor activation (Halberstadt, 2015; Nichols, 2004) . Additionally, marked discrepancies between inositol phosphate hydrolysis activation and other in vitro assays and the in 13 vivo effects of hallucinogens in laboratory animals or humans are well recognized (Nichols, 2004; Saez et al., 1994; Villalobos et al., 2004) . Thus, although most of the effects of hallucinogens are clearly mediated by 5-HT 2A receptor activation (Halberstadt, 2015; Nichols, 2004) , the signaling pathways that mediate these effects
have not yet been conclusively identified (Halberstadt, 2015) . were tested in the present study, was a more potent 5-HT 2A receptor agonist than 2,5-dimethoxy-4-iodoamphetamine (DOI) in vitro but less 14 effective in inducing head-twitch responses in mice (Fantegrossi et al., 2015) . Thus, more in vivo studies are needed to determine the in vivo potency of novel NBOMe drugs.
Within the 2C or NBOMe drug series, para-phenyl substitutions compared with 2C-H or 25H-NBOMe, respectively, enhanced 5-HT 2 receptor binding and activation potency, which was expected based on previous studies (Blaazer et al., 2008; Eshleman et al., 2014; Hansen et al., 2014; Shulgin and Shulgin, 1991) . Interestingly, 5-HT 2A receptor activation potency increased with the size of the 4-substituent (2C-D < 2C-E < 2C-P) within the 2C series (Blaazer et al., 2008; Eshleman et al., 2014) , Thus, NBOMe drugs are unlike LSD, which is a potent 5-HT 1A receptor ligand and full agonist at 5-HT 1A receptors (Nichols, 2004) . Importantly, 5-HT 1A receptors have been shown to contribute to the discriminative stimulus effects of some hallucinogens (Halberstadt, 2015; Nichols, 2004) . Additionally, 5-HT 1A antagonism markedly enhanced the hallucinogenic effects of DMT in humans (Strassman, 1996) .
Accordingly, 5-HT 1A receptor stimulation has been hypothesized to counteract hallucinogenic activity (Halberstadt and Geyer, 2011; Nichols, 2004) , and lower 5-HT 1A receptor stimulation for the NBOMe drugs may further enhance their hallucinogenic drug properties. N-2-methoxybenzyl substitution increased 5-HT 2B
activation, but this is likely not relevant for the psychotropic properties of the NBOMe drugs (Blaazer et al., 2008) . However, 5-HT 2B receptors have been implicated in substance-induced heart valve fibrosis (Bhattacharyya et al., 2009; Setola et al., 2003) , and the 2C and NBOMe drugs may therefore have cardiac toxicity if used chronically.
Because NBOMe drugs produce marked sympathomimetic cardiovascular effects in humans (Wood et al., 2015) , we tested whether these drugs interact with monoamine transporters similarly to cocaine or amphetamines (Simmler et al., 2013; Simmler et al., 2014a) and other novel psychoactive substances (Rickli et al., 2015a; Rickli et al., 2015b; Simmler et al., 2014a; Simmler et al., 2014b) . N-2-methoxybenzyl substitution enhanced monoamine transporter inhibition compared with the 2C drugs.
However, the potency of even the most potent NBOMe drugs at the NET and SERT was low and only in the 5-10 μM range, indicating that amphetamine-type monoamine transporter interactions contribute only little to the cardiostimulant effects of NBOMe drugs.
In addition to their very high 5-HT 2A binding affinity, we found that the NBOMe drugs and LSD had high binding affinity for adrenergic α 1A receptors. 2C drugs have been shown to contract blood vessels (Saez et al., 1994) through direct interactions with serotonergic 5-HT 2 and adrenergic α 1 receptors (Lobos et al., 1992) . The vasoconstrictive potency of 2C drugs does not appear to correlate well with hallucinogenic potency in humans (Saez et al., 1994) or 5-HT 2A receptor activation.
For example, 2C-D had higher affinity for 5-HT 2A receptors compared with 2C-H in the present study but lower potency in contracting the rat aorta (Saez et al., 1994) .
Additionally, 2C-N, which exhibited high affinity for 5-HT 2A receptors but not α 1 receptors in the present study, did not present vasoconstrictive activity (Saez et al., 1994) . These findings and the relatively high affinity of the NBOMe drugs for adrenergic α 1 receptors indicate that these receptors might contribute to the stimulant-type cardiovascular effects that are typically seen in cases of NBOMe drug intoxication (Srisuma et al., 2015; Wood et al., 2015) . Additionally, the behavioral effects of 25I-NBOMe in mice showed a rapid peak (within minutes), whereas the response to 2C-I was relatively flat (Halberstadt and Geyer, 2014) . Thus, such substance characteristics as the higher lipophilicity of NBOMe drugs may further accentuate the clinical drug response. As a result, there is likely a high risk of overdose with NBOMe drugs, and several fatalities have been reported (Hill et al., 2013; Srisuma et al., 2015; Walterscheid et al., 2014; Wood et al., 2015) .
Both the 2C and NBOMe drugs bound to TAAR 1 , with few exceptions. N-2-methoxybenzyl substitution slightly decreased TAAR 1 binding affinity as previously
shown for other N-substitutions in phenethylamines . TAAR 1 modulates psychotropic drug actions. Importantly, methylenedioxymethamphetamine inhibits its own stimulant effects via TAAR 1 activation (Di Cara et al., 2011) . Whether similar TAAR 1 -mediated "auto-inhibition" exists for hallucinogens remains to be determined. One hypothesis is that the lower TAAR 1 activity that is associated with N-2-methoxybenzyl substitution may also enhance psychostimulant drug properties in vivo.
LSD exhibited high affinity for D 1 , D 2 and D 3 receptors, as previously shown (Watts et al., 1995) and in contrast to phenethylamines. D 2 receptors have been shown to contribute to the interoceptive effects of LSD in rats (Halberstadt and Geyer, 2013, 2014) . Values are means of three to four independent experiments and 95% confidence intervals (CI). ns, not shown.
